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An Overview of Peroxisome Proliferator-
Induced Hepatocarcinogenesis
by M. Sambasiva Rao* and Janardan K. Reddy*
Peroxisome proliferators are hepatocarcinogens in rats and mice. Chronic administration ofthese com-
pounds results in the development of altered areas and neoplastic nodules followed by hepatocellular
carcinomas. All three types of hepatic lesions do not express y-glutamyltranspeptidase, glutathione 8-
transferase-P, and a-fetoprotein and are resistant to iron accumulation after overload. The mechanism
by which nongenotoxic peroxisome proliferators induce hepatic tumors is not well understood. It has been
proposed that with continuous administration of peroxisome proliferators, liver cells are subjected to
persistent oxidative stress resulting from marked proliferation of peroxisomes and a differential increase
in the levels of H202 producing (20- to 30-fold) and degrading (2-fold) enzymes. Free oxygen radicals lead
toDNAdamage (bothdirectly andthrough lipid peroxidation) and thus maycause initiation andpromotion
of the carcinogenic process.
Introduction
Epidemiologic studies haveunequivocally established
a close association between exposure to some chemicals
and development of cancer in humans. The best way to
prevent development of tumors is to minimize or, if
possible, completely avoid exposure of humans to such
chemicals. For identification of carcinogenic chemicals,
several short-term in vitro and in vivo tests have been
developed based on the concept that carcinogens lead
to alterations in DNA (1,2). However, there are some
chemicals that elude detection in short-term tests and
produce tumors in animals in long-term experiments.
These compounds are termed nongenotoxic or nonmu-
tagenic carcinogens. Initially, the idea of induction of
tumors by nongenotoxic chemicals was considered a
novelty and not well received. Because of the identifi-
cation of increasing numbers of nongenotoxic carcino-
gens over the last 15 years, the possibility ofinduction
oftumors by chemicals that do not react with DNA has
become a reality and is now well recognized (3-5).
Nongenotoxic carcinogens induce tumors in different
organs and tissues (6). Interestingly, the most often
affected organ is the liver, and there are several ex-
amples ofhepatocarcinogenesis models in rats and mice
using dietary manipulation or chemicals of industrial
and medicinal value (5,7-9). However, the nagging
question that remains unanswered is by what mecha-
nism(s) do these various compounds with different
chemical and functional properties and with no DNA
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binding ability induce tumors? In this article an over-
view ofcurrent status ofhepatocarcinogenesis induced
by peroxisome proliferators, the prototype of nongen-
otoxic carcinogens, is presented. In addition, we briefly
discuss the possible mechanisms involved inperoxisome
proliferator-induced carcinogenesis. This subject is of
considerable importance because peroxisome prolifer-
ators are nongenotoxic and elude detectionbythe avail-
able short-term tests and because, most importantly,
the possible health hazards to humans stemming from
exposuretoperoxisome proliferators eitherthrough-en-
vironmentalcontaminationofplasticizers andherbicides
or through therapeutic use of hypolipidemic drugs.
Peroxisome Proliferators
Peroxisomes are singlemembrane-bound cytoplasmic
organelleswithperoxidativefunctions. Peroxisomesare
present in all mammalian cells except red blood cells.
However, theirnumber, size, and enzyme proffle varies
between different tissues (10). These organelles are
found in large numbers in hepatocytes, followed by
proximal tubular epithelial cells ofthe kidney (7). Per-
oxisomes can be readily induced to proliferate in the
liver cells and to a lesser extent in the kidney cells by
different chemicals which are designated as "peroxi-
some proliferators" (11). Peroxisome proliferators have
a minimal or no effect on other tissues with reference
to the induction of peroxisomes (12). The number of
conditions that lead to peroxisome proliferation is rap-
idlyincreasing: these conditionsinclude dietaryfactors,
hormones, hypolipidemic compounds, phthalate ester
plasticizers, trichloroethylene, andherbicides(7,13-16).
The chemicals, with divergent structures and phar-RAO AND REDDY
macokinetic properties, induce similar types of quali-
tative changes in the liver cells. However, the quanti-
tative response is quite variable, and the degree of
peroxisome proliferation is dependent on the species
and potency of the compound (17-20). The maximum
response is observed in rats and mice. The following
discussion, therefore, will be confined to these two spe-
cies. The mechanism by which such a diverse group of
chemicals induces such a singular response is not une-
quivocally established. Currently available data lead to
the postulation of the existence of specific recognition
molecules in responsive cells (21,22).
Biological Effects of Peroxisome
Proliferators in Liver
Administration of peroxisome proliferators leads to
predictable morphological and biochemical changes that
can be characterized as early "adaptive" and late "car-
cinogenic" effects. During the adaptive phase there is
hepatomegaly associated with peroxisome proliferation
and induction of peroxisomal, endoplasmic reticulum,
and cytosolic enzymes (23). Increase in liverweight and
size is apparent within a few days of administration of
peroxisome proliferator, reaching a steady state by 2
weeks. Hepatomegaly is secondary to hyperplasia and
hypertrophy of hepatocytes (7). Hyperplasia of hepa-
tocytes is short-lived, reaching maximum in a week fol-
lowed by progressive decrease (24,25), whereas hyper-
trophy persists as long as the xenobiotic treatment is
continued. Hypertrophy of hepatocytes is due to a
marked increase in the cytoplasmic volume resulting
mainly from proliferation ofperoxisomes and to a lesser
extent from smooth endoplasmic reticulum (26). Induc-
tion ofperoxisomal enzymes begins within a few hours
afteradministration ofthe peroxisome proliferator (27).
However, the levels ofincrease ofdifferent enzymes is
markedlyvariable. Catalase andurateoxidase activities
are increased about 2-fold, whereas fatty acid 3-oxi-
dation enzyme system is increased 20- to 30-fold. Such
a variation is dependent on the differential regulation
of genes encoding peroxisomal enzymes (11,27). Per-
oxisome proliferators, in addition, also stimulate (laur-
ate hydroxylase, epoxide hydrolase, carnitine palmitoil
transferease) or inhibit (glutathione peroxidase, super-
oxide dismutase) the synthesis of other enzymes
(23,28,29). Persistence ofthese alterations in the levels
of various enzymes appears to contribute significantly
to the development of tumors in the liver.
Hepatocarcinogenicity of
Peroxisome Proliferators
The original description of the carcinogenic effect of
nafenopin in mice by Reddy et al. in 1976 (30) was fol-
lowed by several reports establishing several peroxi-
some proliferators as complete hepatocarcinogens in
rats and mice (7,20,31-38). Chronic administration of
peroxisome proliferators results in the appearance of
liver lesions in a sequential fashion. Altered areas (AA)
appear first, followed by neoplastic nodules (NN,) and
finally hepatocellular carcinomas (HCC) develop. Mor-
phologicalandphenotypicpropertiesoftheselesionsare
well characterized (39-41). In AA and NN there is in-
creased cellularity, crowding ofnuclei, and prominence
of nucleoli. The cytoplasm of cells in AA and NN is
eosinophilic and granular. HCC are usually well differ-
entiated with a trabecular pattern. In 20 to 40% ofthe
animals, HCC metastasize to lungs. AA, NN, and HCC
induced by peroxisome proliferators do not express -y-
glutamyltranspeptidase, glutathione s-transferase-P,
and a-fetoproteinand are resistanttoironaccumulation
after overload. The lack of expression of y-glutamyl
transpeptidase and glutathione s-transferase-P is not
due to drugtoxicity or the presence ofinactive protein,
but is due to failure of derepression of genes encoding
for these enzymes (42). The failure of y-glutamyl tran-
speptidase expression is irreversible and cannot be al-
tered by the administration of genotoxic carcinogens
(43). Similar enzyme patterns are also reported in le-
sions initiated by diethylnitrosamine and promoted by
peroxisome proliferators (35,37). In addition, HCC are
low in the activities of drug metabolizing and detoxi-
fying enzymes and epoxide hydrolase (44).
Initiation Versus Promotion by
Peroxisome Proliferators
An issue that is often raised by some in regard to
peroxisome proliferator-induced hepatocarcinogenesis
is whether these compounds are true initiators or pro-
moters, simply promoting the spontaneously initiated
lesions. This concern is mainly based on two findings:
lack ofgenotoxicity ofperoxisome proliferators and the
long latency period involved in the development of tu-
mors. It is clear that there are several chemicals that
react with DNA and lead to alterations (genotoxic car-
cinogens). However, one hastokeepinmindthatchem-
icals that are nongenotoxic, yet carcinogenic, can lead
to DNA alterations through their biological effects.
Even under normal physiological conditions there are
cellular processes that are inherently mutagenic (45).
The biological effects of nongenotoxic carcinogens can
simply amplify the normally operative mutagenic mech-
anisms and overwhelm the protective defense mecha-
nisms. This is particularly relevant in the case of per-
oxisome proliferators as they markedly enhance the
activity of H202-generating enzymes.
The latency period for the development of HCC
ranges from 50 to 120 weeks and is dependent on the
type and dose of peroxisome proliferator used (32,39).
With potent peroxisome proliferators such as ciprofi-
brate and Wy-14,643, tumors develop as early as 50
weeks. With weak peroxisome proliferators such as
phthalate esters, tumors develop after 90 weeks. The
extended period oftime required for the appearance of
tumorsisnotpeculiartoperoxisomeproliferators. Even
with genotoxic carcinogens, the incidence and latency
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period depends onthe potencyandthe dose ofthechem-
ical (46). Carcinogenic potency between different gen-
otoxic chemicals is variable by several orders of mag-
nitude (47,48).
The results ofarecent study clearlyestablish therole
ofperoxisomeproliferatorsasinitiators. Administration
ofciprofibrate to 24-week-old and 1-year-old rats for 60
weeksresulted inanidentical tumorincidence and num-
ber oftumors per liver (49). These findings negate the
assumption that peroxisome proliferators are selective
tumor promoters because of the absence of increased
tumor incidence in 1-year-old rats. If peroxisome pro-
liferators are only promoters of spontaneous lesions, a
higher tumor incidence should have been observed in
old rats because of expected increase in presumably
spontaneously initiated lesions when compared to
younger animals (50).
Mechanism of Carcinogenesis by
Peroxisome Proliferators
Because of the nongenotoxic nature of peroxisome
proliferators, it has been postulated that their carcin-
ogenic effect may be dependent on two major biological
effects, i.e., cell proliferation and peroxisome prolifer-
ation(7,51,52). Sincethehepaticcellhyperplasiaispres-
ent only during early adaptive state and decreases
thereafter, it is unlikely to have a significant effect on
the development oftumors at a much latertime (24,25).
In addition, the type ofcell proliferation caused by per-
oxisome proliferators is a mitogenic response, where
the cells are less susceptible to carcinogens, unlike cells
dividing as a compensatory response (53).
Theexperimentalevidenceinculpatingtheroleofper-
oxisome proliferation in hepatocarcinogenesis is cer-
tainly more convincing. Persistent peroxisome prolif-
eration associated with a marked increase in H202
generating enzymes and decrease in free radical scav-
enging enzymes leads to oxidative stress (7,27,28,54).
Increases in the levels ofH202 and hydroxyl radicals in
liver cells in peroxisome proliferator-treated rats and
mice have been documented (55,56). Free oxygen rad-
icals lead to alterations in DNA, lipid peroxidation in
membranes, and critical sulfhydryl bonds in proteins
(57,58). H202 was shown to induce DNA strand breaks
in hepatocytes maintained in culture (59). Chronic
administration of a peroxisome proliferator was also
shown to lead to increased levels of 8-hydroxydeoxy-
guanosine, an indicator of free radical damage (60,61).
Additional DNA alterations caused by peroxisome pro-
liferators include reduction in the levels ofI-compounds
in the liver DNA (61). Decreased levels ofI-compounds
may play a significant role in the initiation phase of
carcinogenesis.
With peroxisome proliferators there is a good cor-
relation between the potency of peroxisome prolifera-
tion and hepatocarcinogenicity. Because of this strong
association, and in the absence of any other reliable
short-term tests, it is prudent to screen nongenotoxic
chemicals for their ability to induce peroxisome prolif-
eration either in in vivo or in cell culture systems.
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